https://www.biospace.com/pmv-pharmaceuticals-pynnacle-phase-i-data-of-rezatapopt-in-advanced-ovarian-cancer-featured-in-late-breaking-oral-presentation-at-2024-sgo-annual-meeting-on-women-s-cancer
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in...
Mar 18, 2024 - PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies...
https://www.hmpgloballearningnetwork.com/site/onc/videos/rezatapopt-shows-clinical-promise-tp53-mutated-ovarian-cancer
Rezatapopt Shows Clinical Promise in TP53-Mutated Ovarian Cancer
Alison Schram, MD, discusses results from the phase 2 PYNNACLE trial which assessed rezatapopt in TP53 Y220C mutated advanced or metastatic ovarian cancer....
rezatapoptshowsclinicalpromisetp53